Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Accumulated Expenses data on file, last reported at $12.6 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 2.38% year-over-year to $12.6 million; the trailing twelve-month figure through Dec 2025 stood at $12.6 million (down 2.38% YoY), and the FY2025 full-year result was $12.6 million, down 2.38% from the prior year.
• Accumulated Expenses eased to $12.6 million in Q4 2025, from $34.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $38.5 million in Q4 2023 to a low of $4.5 million in Q1 2021.
• A 5-year average of $13.2 million and a median of $11.5 million in 2021 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 66.46% in 2024 and surged 163.16% in 2025, its largest moves.
• Tracing STRO's Accumulated Expenses over 5 years: stood at $11.4 million in 2021, then grew by 29.32% to $14.8 million in 2022, then surged by 160.59% to $38.5 million in 2023, then plunged by 66.46% to $12.9 million in 2024, then decreased by 2.38% to $12.6 million in 2025.
• Business Quant data shows STRO's Accumulated Expenses at $12.6 million in Q4 2025, $34.7 million in Q3 2025, and $11.8 million in Q2 2025.